AVOS Life Sciences estimates that by 2013, biologics will account for 40% of the 14 major drug companies’ portfolios of branded drugs with more than $500 million in yearly sales, up from 26% last year. For the period, both GlaxoSmithKline (GSK) and Abbott will be among the top three firms in terms of sales and growth rate. Revenues from these portfolios is forecasted to grow 21%, 14% and 12% for GSK, Bristol-Myers and Abbott, respectively. Roche is expected to be the largest revenue contributor from these products, with $10.3 billion in sales. As a percentage of a company’s total product sales, Amgen will continue to have the largest share of biologics at 95% in 2013, down from 96% in 2008. Roche, Wyeth and Abbott will have the next three largest percentages at 82%, 77% and 54%, respectively.

Source: Nature Reviews Drug Discovery